Concepedia

Arris J. Henderson

AJ

Statistics

Publications

8

Citations

1.3K

H-Index

8

Active since

1993

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bayer (United States)

Arris J. Henderson is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, cancer pharmacology, and oncology.

Publications per year

1993–2006

8

Publications

8

Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates

Pamela A. Trail, David Willner, Shirley J. Lasch et al. · Science · 1993 · 554 citations

, , +16

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Yong S. Chang, Jalila Adnane, Pamela A. Trail et al. · Cancer Chemotherapy and Pharmacology · 2006 · 465 citations

, , +16

Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.

Joseph G. Naglich, Maria Jure‐Kunkel, Elora Gupta et al. · PubMed · 2001 · 114 citations

, , +12

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

Pamela A. Trail, David Willner, Jay O. Knipe et al. · PubMed · 1997 · 56 citations

, , +17

Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.

Pamela A. Trail, David Willner, A. Bianchi et al. · PubMed · 1999 · 44 citations

, , +11

1–5 of 8